quinazolines has been researched along with cediranib in 251 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 53 (21.12) | 29.6817 |
| 2010's | 173 (68.92) | 24.3611 |
| 2020's | 25 (9.96) | 2.80 |
| Authors | Studies |
|---|---|
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Barnett, S; Barry, ST; Beck, S; Bigley, AL; Boffey, SJ; Brave, SR; Chester, R; Cooper, L; Curwen, JO; Dukes, M; Hennequin, LF; Jackson, JA; James, NH; Jürgensmeier, JM; Kendrew, J; Kilburn, LL; Ogilvie, DJ; Richmond, GH; Smith, NR; Taylor, ST; Valentine, PJ; Wadsworth, PF; Walker, M; Wedge, SR | 1 |
| Agarwala, SS; Tawbi, H | 1 |
| Berman, A; Chow, CK; Denduluri, N; Swain, SM; Tan, AR; Walshe, J; Yang, SX | 1 |
| Agarwal, B; Badve, S; Hutchins, GD; Mehrotra, S; Miller, KD; Miller, M; Mock, BH; Sledge, GW; Zheng, QH | 1 |
| Alferez, D; Goodlad, RA; Mandir, N; Poulsom, R; Pyrah, IT; Ryan, AJ; Smith, NR; Watkins, AJ; Wedge, SR; Wilkinson, RW | 1 |
| Gasparini, G; Longo, R; Sarmiento, R | 1 |
| Giaccone, G; Hoekman, K; Kater, M; Manoliu, RA; Meijerink, MR; van Cruijsen, H; van Schaik, C; van Waesberghe, JH | 1 |
| Albert, JM; Cao, C; Geng, L; Ivy, PS; Johnson, DH; Lu, B; Sandler, A | 1 |
| Gutin, PH; Hormigo, A; Rafii, S | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M | 1 |
| Babur, M; Shannon, AM; Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 2 |
| Courtright, J; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Tajbakhsh, M; Wu, J | 1 |
| Conry, S; Hutcheon, D; Morris, C; Puchalski, T; Roth, B; Ryan, CJ; Small, EJ; Stadler, WM | 1 |
| Bradley, DP; Checkley, D; Kendrew, J; Kuribayashi, H; Tessier, JL; Waterton, JC; Wedge, SR | 1 |
| Arao, T; Fukuoka, K; Kimura, H; Komatsu, T; Nishio, K; Saijo, N; Sasaki, H; Takeda, M; Tamura, T; Yamada, Y; Yanagihara, K; Yokote, H | 1 |
| Bozec, A; Formento, P; Hofman, P; Lassalle, S; Lippens, C; Milano, G | 1 |
| Blum, H; Drevs, J; Harder, J; Jürgensmeier, JM; Medinger, M; Mross, K; Puchalski, TA; Robertson, J; Saunders, O; Siegert, P; Strecker, R; Unger, C; Young, H; Zirrgiebel, U | 1 |
| Fooshee, D; Gomez-Rivera, F; Jasser, SA; Kim, S; Myers, JN; Santillan-Gomez, AA; Younes, MN; Zhao, M | 1 |
| Hanrahan, EO; Heymach, JV | 1 |
| Barry, ST; Copley, C; James, NH; Jürgensmeier, JM; Kendrew, J; Oakley, I; Smith, NR; Wainwright, A; Wedge, SR; Womersley, LM | 1 |
| Zhu, AX | 1 |
| de Gruijl, TD; Giaccone, G; Hoekman, K; Kuenen, BC; Scheper, RJ; Stam, AG; van Cruijsen, H; van den Eertwegh, AJ | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Lee, CB; Socinski, MA | 1 |
| Curwen, JO; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Wedge, SR | 1 |
| Heymach, JV; Nikolinakos, P | 1 |
| Alitalo, K; Heckman, CA; Holopainen, T; Jeltsch, M; Jürgensmeier, JM; Keskitalo, S; Wedge, SR; Wirzenius, M; Ylä-Herttuala, S | 1 |
| Fukumura, D; Hoshida, T; Jain, RK; Kozak, KR; Kuo, AH; Liao, S; Lobo, J; Padera, TP | 1 |
| Bozec, A; Cayre, A; Dental, C; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Gros, FX; Milano, G; Penault-Llorca, F | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Bradley, DP; Jürgensmeier, JM; Kilburn, L; Lacey, T; Mills, J; Odedra, R; Scott, M; Tessier, JJ; Wedge, SR | 1 |
| Döme, B; Magyar, M | 1 |
| David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ | 1 |
| Brazelle, WD; Jürgensmeier, JM; Siemann, DW | 1 |
| Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Tao, LY; Wang, F; Yan, YY | 1 |
| JuanYin, J; Kelly, K; Koretsky, A; Munasinghe, J; Shapiro, E; Tracy, K; Zhang, L | 1 |
| Boku, N; Fujiwara, Y; Murakami, H; Nokihara, H; Puchalski, TA; Shin, E; Takahashi, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N; Yamazaki, K | 1 |
| Batchelor, TT; di Tomaso, E; Duda, DG; Duyverman, AM; Farrar, CT; Fukumura, D; Jain, RK; Kamoun, WS; Lacorre, DA; Lahdenranta, J; Ley, CD; Munn, LL; Sorensen, AG | 1 |
| Batchelor, TT; di Tomaso, E; Duda, DG; Gerstner, ER; Ivy, P; Jain, RK; Loeffler, JS; Ryg, PA; Sorensen, AG | 1 |
| Cassidy, J; Lindsay, CR; MacPherson, IR | 1 |
| Ancukiewicz, M; Batchelor, TT; Chen, PJ; di Tomaso, E; Duda, DG; Jain, RK; Jennings, D; Lahdenranta, J; Sorensen, AG; Wang, M; Wen, PY; Yeo, P; Zhang, WT | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Batchelor, TT; Dietrich, J; Wang, D | 1 |
| Berdel, WE; Collins, B; Ehninger, G; Fiedler, W; Heuser, M; Jürgensmeier, JM; Mesters, R; Puchalski, TA; Robertson, JD; Serve, H; Zirrgiebel, U | 1 |
| Brown, AM; Ciardiello, F; Eckhardt, SG; Jürgensmeier, JM; Morelli, MP; Pitts, TM; Ryan, A; Tentler, JJ | 1 |
| Berkenblit, A; Berlin, S; Campos, S; Cannistra, SA; Hill, M; Horowitz, N; Humphreys, BD; Ivy, P; Krasner, C; Lee, H; Lee, J; Matulonis, UA; Penson, RT; Roche, M; Sullivan, L; Tran, C; Tyburski, K; Whalen, C; Zarwan, C | 1 |
| Blum, HE; De Bono, J; Drevs, J; Fiedler, W; Fielding, A; Hoekman, K; Langenberg, MH; Le Maulf, F; Robertson, J; Schellens, JH; Unger, C; van Herpen, CM; Voest, EE | 1 |
| Arnold, A; Ciuleanu, TE; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Frymire, E; Gauthier, I; Goss, GD; Ho, C; Laberge, F; Laurie, SA; Lee, CW; Leighl, NB; Noble, J; Seymour, L; Shepherd, FA; Vincent, MD; Walde, D; Zukin, M | 1 |
| Wachsberger, P; Yan, K; Yu, Y | 1 |
| Drevs, J; Esser, N; Jürgensmeier, JM; Medinger, M; Ryan, A; Zirrgiebel, U | 1 |
| Berlin, ST; Humphreys, BD; Ivy, P; Matulonis, UA; Penson, RT; Robinson, ES; Tyburski, K | 1 |
| Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO | 1 |
| Batchelor, TT; Chen, PJ; Gerstner, ER; Jain, RK; Sorensen, G; Wen, PY | 1 |
| Drake, C; Harrison, M; Lenz, EM; Pollard, CR; Schulz-Utermoehl, T; Spear, M; Ward, M | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Chea, H; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Eichler, AF; Exarhopoulos, A; Gerstner, E; Hochberg, FH; Ivy, P; Jain, RK; Loeffler, JS; Louis, DN; Moses, MA; Plotkin, SR; Sorensen, AG; Wen, PY | 1 |
| Kim, SY; Niswander, LM | 1 |
| Belani, CP; Gandara, DR; Govindan, R; Ivy, SP; Koczywas, M; Longmate, J; Mack, PC; Ramalingam, SS; Vokes, EE | 1 |
| Gadgeel, S; Guthrie, T; Liu, Q; Lorusso, P; Puchalski, T; Shields, AF; Vaishampayan, U; Xu, J | 1 |
| Bushby, N; Harrison, M; Jordan, A; Pattison, C; Pollard, CR; Rollison, H; Sarda, S; Schulz-Utermoehl, T; Spear, M; Ward, M | 1 |
| Stupp, R; Tabatabai, G | 1 |
| Kelly, K; Linnoila, RI; Munasinghe, J; Yin, JJ; Zhang, L | 1 |
| Bowen, D; Byrd, J; Call, T; Erlichman, C; Ghosh, A; Hanson, C; Jelinek, D; Kay, N; Laplant, B; Laumann, K; Shanafelt, T; Villalona-Calero, M; Wu, W; Zent, C | 1 |
| Adamson, PC; Aplenc, R; Bagatell, R; Balis, FM; Brown, KH; Chuk, MK; Dombi, E; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Kromplewski, M; Marotti, M; Wenrich, B; Widemann, BC | 1 |
| Daroczi, B; Dicker, AP; Lawrence, YR; Liu, Y; Wachsberger, PR; Xu, X | 1 |
| Cheung, S; Evans, J; Fielding, A; Harris, A; Jackson, A; Jayson, GC; Kelly, C; Middleton, M; Mitchell, CL; O'Connor, JP; Parker, GJ; Roberts, C; Rudman, S; Spicer, J; Tessier, J; Watson, Y; Young, H | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Andronesi, OC; Auluck, PK; Batchelor, TT; di Tomaso, E; Duda, DG; Fazlollahi, L; Frosch, MP; Hedley-Whyte, ET; Jain, RK; Kamoun, WS; Plotkin, SR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Catana, C; Farrar, CT; Jain, RK; Kamoun, WS; Kim, YR; Kwon, SJ; Ley, CD; Rosen, BR; Sorensen, AG | 1 |
| Alberts, SR; Dakhil, SR; Fitch, TR; Gross, HM; Kim, GP; Morlan, BW; Nair, S | 1 |
| Ashton, S; Barnes, C; Barry, ST; Brave, SR; Broadbent, N; Dudley, P; Farnsworth, CL; Hennequin, L; James, NH; Jürgensmeier, JM; Kendrew, J; Ogilvie, DJ; Ratcliffe, K; Shibuya, M; Silva, JC; Sproat, G; Taylor, S; Wainwright, A; Wedge, SR; Wilson, Z | 1 |
| Batchelor, TT; Bjornerud, A; Borra, RJ; Emblem, KE; Jain, RK; Mouridsen, K; Sorensen, AG | 1 |
| Andronesi, OC; Batchelor, TT; Catana, C; Jain, RK; Jennings, DL; Kim, H; Ratai, EM; Sorensen, AG | 1 |
| Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X | 1 |
| Billups, CA; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Maris, JM; Morton, CL; Smith, MA; Wu, J | 1 |
| Ahluwalia, MS; Wen, PY | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K | 1 |
| Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Chansky, K; Dasilva, MA; Gadgeel, SM; Gandara, DR; Garland, LL; Redman, M; Tsao, AS; Verschraegen, CF; Wozniak, AJ | 1 |
| Brown, KH; Drevs, J; Eberhardt, WE; Gauler, TC; Le Scouiller, S; Marotti, M; Schneider, V; Schultheis, B; Strumberg, D; Trarbach, T | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Elmquist, WF; Oberoi, RK; Wang, T | 1 |
| Ancukiewicz, M; Batchelor, TT; Emblem, KE; Ivy, P; Jain, RK; Jennings, D; Kim, H; Polaskova, P; Sorensen, AG; Wang, M; Wen, PY | 1 |
| Bonfil, RD; Cher, ML; Conley-LaComb, MK; Heath, E; Jung, YS; Kim, CJ; Kim, HR; Najy, AJ; Saliganan, A; Won, JJ | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| de Jong, I; Gore, ME; Hawkins, R; Jürgensmeier, JM; Mookerjee, B; Mulders, P; Nathan, P; Osanto, S; Pike, L; Porfiri, E; Protheroe, A; van Herpen, CM | 1 |
| Baker, LC; Boult, JK; Burrell, JS; Halliday, J; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Agarwal, S; Elmquist, WF; Wang, T | 1 |
| Collins, M; Gore, JC; Halliday, J; Huszar, D; Lawson, D; Loveless, ME; Nadella, MV; Reimer, C; Waterton, JC; Yankeelov, TE | 1 |
| Döme, B; Török, S | 1 |
| Beijnen, JH; Durmus, S; Schellens, JH; Schinkel, AH; Sparidans, RW; Xu, N | 1 |
| Bokacheva, L; Carlin, S; Halliday, J; Kotedia, K; Koutcher, JA; Le, CH; Reese, M; Ricketts, SA | 1 |
| Rudà, R; Soffietti, R; Trevisan, E | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Agamah, E; Campbell, NP; Gandara, DR; Gitlitz, BJ; Kindler, HL; Koczywas, M; Kunnavakkam, R; Leighl, N; Stadler, WM; Thomas, SP; Vincent, MD; Vokes, EE | 1 |
| Ang, JE; Brunetto, A; Castellano, I; Collins, DJ; deBono, JS; deSouza, NM; Ghiorghiu, D; Kaye, SB; Leach, MO; Mann, H; Marley, S; Mears, D; Messiou, C; Morgan, VA; Orton, M; Papadatos-Pastos, D; Tessier, J; Tunariu, N; Young, H | 1 |
| Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| de Groot, J; Fuller, G; Heimberger, AB; Kong, LY; Liang, J; Piao, Y; Qiao, W; Wei, J | 1 |
| Adamson, D; Brown, K; Chen, E; Evans, TR; Hotte, S; Kollmansberger, C; Lassen, U; Meyer, T; Miller, WH; Nielsen, DL; Rafi, R; Sawyer, MB; Spicer, J | 1 |
| Brown, KH; de Jonge, MJ; Desar, IM; Lassen, U; Marotti, M; van Herpen, CM | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP | 1 |
| Chen, EX; Haider, MA; Halford, R; Hotte, SJ; Ivy, SP; Kollmannsberger, C; Mackenzie, MJ; Moore, MJ; Mukherjee, SD; Murray, N; Sridhar, SS; Tannock, IF; Wang, L | 1 |
| Jürgensmeier, JM; Kendrew, J; Logié, A; Odedra, R; Ogilvie, DJ; Pearsall, S; Taylor, PJ; Wedge, SR | 1 |
| Abrams, TA; Ancukiewicz, M; Bhargava, P; Blaszkowsky, LS; Duda, DG; Fuchs, CS; Jain, RK; Knowles, M; McCleary, NJ; Meyerhardt, JA; Muzikansky, A; Regan, E; Ryan, DP; Sahani, DV; Sheehan, S; Supko, JG; Vasudev, E; Zhu, AX | 1 |
| Adelberg, D; Chau, CH; Choyke, PL; Dahut, WL; Figg, WD; Gulley, JL; Karakunnel, JJ; Madan, RA; Mulquin, M; Parnes, HL; Spencer, SD; Steinberg, SM; Turkbey, IB; Wright, J | 1 |
| Brooks, L; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Robertson, JD; Schmoll, HJ; Taboada, M; Wilson, D | 1 |
| Cho, BC; Kim, HR; Lim, SM; Shim, HS; Soo, RA | 1 |
| Brooks, L; Dearden, S; Hoff, PM; Jürgensmeier, JM; McWalter, G; Morgan, SR; Robertson, JD; Smith, JC; Wilson, D | 1 |
| Allen, D; Choyke, P; Doroshow, JH; Helman, L; Hose, CD; Ivy, SP; Kinders, RJ; Kummar, S; Lawrence, S; Monks, A; Polley, EC; Simon, R; Steinberg, SM; Turkbey, IB | 1 |
| Ballman, K; Sleijfer, S; Verweij, J | 1 |
| Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Batchelor, TT; de Groot, J; Reardon, DA | 1 |
| Alencar, VM; Audeh, MW; Brown, K; Chan, A; de Oliveira, C; Hyams, DM; Klein, P; Lombard, J; Mookerjee, B; Snyder, R; Vinholes, J; Xu, J | 1 |
| Birrer, M; Buss, MK; Dahlberg, SE; Fleming, GF; Ivy, P; Lee, H; Liu, JF; Matulonis, UA; Tolaney, SM; Tyburski, K; Whalen, C; Winer, E | 1 |
| Barry, ST; Bradford, JR; Brown, H; Carr, TH; Delpuech, O; Dry, JR; Farren, M; Gibson, NJ; Powell, SJ; Runswick, S; Smith, NR; Wappett, M; Weston, SL | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J | 1 |
| Batchelor, TT; Bjornerud, A; Borra, RJ; Emblem, KE; Farrar, CT; Ivy, P; Jain, RK; Jennings, D; Mouridsen, K; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Baron, K; Brundage, R; Elmquist, W; Wang, T; Zhong, W | 1 |
| Gillespie, GY; Green, SC; Lobo, MR; Pike, MM; Schabel, MC; Woltjer, RL | 1 |
| Amantini, C; Berardi, R; Burattini, L; Cascinu, S; Conti, A; Muzzonigro, G; Santoni, G; Santoni, M | 1 |
| Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK | 1 |
| Ancukiewicz, M; Batchelor, TT; Chi, AS; Dietrich, J; Duda, DG; Eichler, AF; Emblem, KE; Gerstner, ER; Hochberg, FH; Iafrate, AJ; Ivy, SP; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Loeffler, JS; Lu-Emerson, C; Pinho, MC; Plotkin, SR; Polaskova, P; Rosen, BR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Bar, J; Brooks, L; Cunningham, D; Goss, GD; Jürgensmeier, JM; Morgan, S; Robertson, J; Spencer, S | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| Boers-Sonderen, MJ; Mulder, SF; Punt, CJ; van der Heijden, HF; van Herpen, CM; Vissers, KC | 1 |
| Honda, M; Isobe, T; Komatsu, R; Kuramoto, S; Shindoh, H; Tabo, M | 1 |
| Barquin, E; Collins, B; Gardner, K; Judson, I; Jürgensmeier, JM; Leahy, M; Marotti, M; Scurr, M; Young, H | 1 |
| Anderes, K; Camacho, LH; Culotta, KS; Davis, DW; Ekmekcioglu, S; Falchook, GS; Fu, S; Garrido-Laguna, I; George, GC; Hong, DS; Kurzrock, R; Liu, W; Moulder, SL; Naing, A; Percy Ivy, S; Piha-Paul, S; Tsimberidou, AM; Wen, Y; Wheler, JJ | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Chu, QS; Hennig, R; Kim, CA; Price-Hiller, J; Sawyer, MB; Spratlin, JL; Tankel, K | 1 |
| Furube, E; Itoh, M; Mannari, T; Miyata, S; Morita, S; Nishikawa, K; Yoshida, A | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Shaw, R; Spencer, SK | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, H; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, S; Obermayer, L; Quy, P; Rimel, B; Whalen, C; Winer, EP | 1 |
| Erlichman, C; Flynn, PJ; Juckett, MB; Jumonville, A; LaPlant, B; Mattison, R; Moreno-Aspitia, A | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Gillespie, GY; Lobo, MR; Pike, MM; Wang, X; Woltjer, RL | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Batchelor, TT; Duda, DG; Emblem, KE; Gerstner, ER; Jain, RK; Loeffler, JS; Lu-Emerson, C; Taylor, JW | 1 |
| Schmidt, C | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Biagi, J; Fleming, GF; Hirte, H; Ivy, SP; Lheureux, S; McGill, S; Morgan, R; Oza, AM; Sugimoto, A; Wang, L | 1 |
| Jin, ZX; Liu, F; Liu, YX; Min, SY; Wang, L; Zhang, XX; Zhu, ZL; Zuo, Z | 1 |
| Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X | 1 |
| Bronshtein, T; Haber, T; Machluf, M; Shivinsky, A | 1 |
| Addison, CL; Bar, J; Bradbury, PA; Dimitroulakos, J; Ding, K; Goss, GD; Han, L; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Wadekar, R; Weber, AM | 1 |
| Belotti, D; Bettolini, R; Bizzaro, F; Cesca, M; Decio, A; Giavazzi, R; Porcu, L; Taraboletti, G; Ubezio, P | 1 |
| Bender, D; Darus, CJ; Delmore, JE; Gray, HJ; Hunter, MI; Lankes, HA; Leslie, KK; Mannel, RS; McCourt, CK; Reyes, HD; Rotmensch, J; Samuelson, MI; Schilder, JM; Sill, MW | 1 |
| Banerjee, A; Boyett, JM; Chi, S; Fahey, F; Fouladi, M; Goldman, S; Jakacki, R; Kieran, MW; Kun, L; Moses, M; Onar-Thomas, A; Packer, RJ; Poussaint, TY; Stewart, CF; Turner, DC; Vajapeyam, S; Wu, S | 1 |
| Collins, D; deSouza, N; Leach, MO; Messiou, C; Morgan, VA; Orton, MR; Tessier, J; Young, H | 1 |
| Cima, MJ; Hochberg, FH; Ong, Q | 1 |
| Allen, D; Bokobza, SM; Devery, AM; Jiang, Y; Kersemans, V; Ryan, AJ; Smart, S | 1 |
| Collins, DJ; Darcy, J; Desouza, N; Leach, MO; Messiou, C; Orton, MR; Rata, M; Tunariu, N; Young, H | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Amzallag, A; Baniya, S; Benes, CH; Cooper, ZA; Fisher, DE; Flaherty, KT; Frederick, DT; Friedman, AA; Haber, DA; Hargreaves, L; Igras, V; Lawrence, DP; Piris, A; Pruteanu-Malinici, I; Ramaswamy, S; Wargo, JA | 1 |
| Banerjee, S; Carty, K; Davidson, S; Dive, C; Flubacher, M; Gourley, C; Hudson, E; Jackson, D; Jankowska, P; Lord, R; McCartney, E; McCormack, M; Paul, J; Powell, M; Rai, D; Reed, N; Symonds, RP; West, CML | 1 |
| Barry, ST; Campbell, H; Critchlow, SE; Eberlein, C; Farren, M; Frith, J; Huby, R; Kendrew, J; Michopoulos, F; Morgan, S; Patel, B; Pommier, AJ; Robertson, J; Smith, NR; Smith, PD; Wappett, M; Womack, C | 1 |
| Gillespie, GY; Grafe, MR; Kukino, A; Lobo, MR; Pike, MM; Schabel, MC; Springer, CS; Tran, H; Woltjer, RL | 1 |
| Bracchi, C; De Medici, C; Gasparri, ML; Imboden, S; Marchetti, C; Mueller, MD; Muzii, L; Palaia, I; Panici, PB; Papadia, A; Ruscito, I | 1 |
| Ackerman, C; Beltran, L; Bhal, A; Boleti, E; Brown, J; Chowdhury, S; Crabb, S; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Webb, A | 1 |
| Gajewski, T; Hui, J; McWhirter, E; Oza, A; Pond, G; Quirt, I; Wang, L | 1 |
| Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Matulonis, UA | 1 |
| Clark, E; Cook, A; Eisenhauer, E; Embleton, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Parmar, MKB; Perren, TJ; Raja, F; Rustin, GJS; Stark, D; Swart, AM; Vaughan, M | 1 |
| Amoozgar, Z; Batchelor, TT; Batista, A; Chatterjee, S; Datta, M; Duda, DG; Farrar, CT; Fukumura, D; Goveia, J; Huang, Y; Jain, RK; Jung, K; Kamoun, WS; Kirkpatrick, ND; Kloepper, J; Leow, CC; Marijt, KA; Muzikansky, A; Peterson, TE; Seano, G; Snuderl, M; Vardam, T; Xu, L | 1 |
| Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K | 1 |
| Bordinhão, AL; Evangelista, AF; Macedo, T; Marques, MM; Oliveira, RJ; Reis, RM; Silveira, HC | 1 |
| Li, J; Masson, E; McCormick, A; Tang, W | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Ceelen, W; Descamps, B; Melsens, E; Pattyn, P; Rosseel, N; Vanhove, C; Verberckmoes, B | 1 |
| Al-Huniti, N; Henningsson, A; Li, J; Masson, E; Tang, W | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Annunziata, CM; Botesteanu, DA; Cao, L; Cimino-Mathews, A; Figg, WD; Harrell, MI; Ho, TW; Houston, N; Kohn, EC; Lee, JM; Lipkowitz, S; Nguyen, J; Ogurtsova, A; Peer, CJ; Swisher, EM; Taube, JM; Thompson, E; Xu, H; Zimmer, A | 1 |
| Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II | 1 |
| Gao, H; Hu, C; Liu, R; Ruan, S; Wang, R; Xiao, W; Yu, W | 1 |
| Banerjee, S; George, A; Marquina, G; Orbegoso, C | 1 |
| Doh, I; Lee, DW; Lee, SY; Nam, DH; Ryu, GH | 1 |
| Al-Huniti, N; Li, J; Masson, E; Petersson, K; Tang, W | 1 |
| Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
| Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Elinoff, JM; Kleiner, DE; Lee, JM; Peer, CJ; Pratt, D; Solomon, MA; Suffredini, DA | 1 |
| Giri, S; Huang, PH; Korayem, Y; Lin, ZP; Lo, YC; LoRusso, P; Moscarelli, J; Ratner, ES; Xiong, A; Zhu, YL | 1 |
| Gao, H; Hu, C; Liu, R; Qin, L; Su, D; Wang, G; Yang, C; Yang, X; Yang, Y; Yu, M; Zhou, Y | 1 |
| Bonam, M; Ivy, SP; Killiam, B; Kohn, EC; Lee, JM; Liu, JF; Mari, K; Milenkova, T; Phillips, R; Strock, E | 1 |
| Ackerman, C; Bahl, A; Beltran, L; Boleti, E; Brown, J; Chowdhury, S; Crabb, SJ; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Shepherd, STC; Webb, A; Wimalasingham, A | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Curtis, J; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, SR; Rimel, BJ; Whalen, C | 1 |
| Seaman, SR; Wason, JM | 1 |
| Gonzalez-Martin, A; Lorusso, D; Pignata, S | 1 |
| Alcindor, T; Awan, A | 1 |
| Anderson, J; Barone, G; Blackledge, MD; Carceller, F; Chesler, L; Clarke, M; Jamin, Y; Jerome, NP; Koers, A; Koh, DM; Marshall, LV; McErlean, CM; McHugh, K; Moreno, L; Pearson, ADJ; Poon, E; Robinson, SP; Sebire, N; Vaidya, SJ; Yuan, Y; Zormpas-Petridis, K | 1 |
| Carty, K; Davidson, S; Dive, C; Jayson, GC; McCartney, E; Paul, J; Rai, D; Simpson, K; Symonds, P; Taylor, S; Tugwood, J; West, C; Zhou, C | 1 |
| Furube, E; Hiratsuka, D; Kurganov, E; Miyata, S; Morita, M | 1 |
| Glazer, PM; Gueble, SE; Kaplan, AR; Kim, H; Liu, Y; Oeck, S; Yun, Z | 1 |
| Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A | 1 |
| Benson, C; Bhadri, V; Bliss, JM; Campbell-Hewson, Q; Cubedo, R; Dangoor, A; Fox, L; Hennig, I; Jarman, K; Joubert, W; Judson, I; Kernaghan, S; Kilburn, L; Leahy, M; López Pousa, A; Martinez Trufero, J; McNeil, C; Morden, JP; Seddon, B; Snowdon, C; Tattersall, M; Toms, C | 1 |
| Pasquali, S; Stacchiotti, S | 1 |
| Hill, SJ; Kilpatrick, LE; Peach, CJ; Woolard, J | 1 |
| Allen, J; Backen, AC; Connell, J; Dive, C; Jackson, A; Jayson, GC; Li, K; Manoharan, P; Marti, FEM; Misra, V; Mistry, H; O'Connor, J; Ortega, F; Renehan, AG; Saunders, MP; Simpson, KL; Stratford, I; Underhill, S; Williams, KJ | 1 |
| Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A | 1 |
| Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS | 1 |
| Deane, E; Embleton-Thirsk, A; Farrelly, L; Kaplan, R; Ledermann, J; Parker, J; Parmar, M; Popoola, B; Rustin, G; Sydes, M; Townsend, S | 1 |
| Box-Noriega, B; Fossella, FV; Gadgeel, S; Gandara, DR; Heymach, JV; Hueftle, JG; Kelly, K; Lu, C; Miao, J; Redman, MW; Tsao, AS; Velasco, MR; Vogelzang, NJ; Wistuba, II | 1 |
| Chen, AP; Cohen, JW; Derdak, J; Dombi, E; Dompierre, J; Glod, J; Goodwin, A; Kummar, S; O'Sullivan Coyne, G; Onukwubiri, U; Steinberg, SM; Widemann, BC | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Bernards, N; Creemers, GJ; de Hingh, IHJT; Legué, LM; Lemmens, VEPP; van Erning, FN | 1 |
| Black, SN; Jones, MF; McFarlane, I; Pettersen, A; Roberts, R; Wheatcroft, HP | 1 |
| Baietti, MF; Criem, N; Impens, F; Lechat, B; Pandolfi, S; Quarck, R; Sablina, AA; Sewduth, RN; Sheryazdanova, A; Steklov, M; Zhao, P | 1 |
| Alishahi, Z; Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Karimi, B; Kashani, B; Momeny, M; Mousavi, SA; Mousavipak, SH; Nasrollahzadeh, A; Sabourinejad, Z; Sankanian, G; Shamsaiegahkani, S; Yousefi, H; Zandi, Z | 1 |
| Arthur-Darkwa, E; Burnett, E; Counsell, N; El-Khouly, F; Elyashiv, O; Farrelly, L; Feeney, A; Gourley, C; Jayson, GC; Ledermann, J; Macdonald, I; Mileshkin, L; Neto, A; Nicum, S; Parmar, G | 1 |
| Collins, L; Dobbie, S; Dunn, R; Holmes, J; Mansouri, A; McGregor, N; Nicum, S | 1 |
| Deane, E; Embleton-Thirsk, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Oza, A; Parmar, MKB; Perren, TJ; Popoola, B; Rustin, GJS; Swart, AM; Vaughan, M | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Cardin, DB; Glazer, PM; Grossman, SR; Ivy, SP; Kato, S; Kim, JW; LoRusso, PM; Shyr, Y; Vaishampayan, UN | 1 |
| Gan, L; Guo, M; Guo, Z; Liu, Z; Si, J; Xie, Y; Zhang, H; Zhang, J; Zhao, J | 1 |
| Chanana, P; Dood, R; Haemmerle, M; Holland, EC; Lazar, AJ; Lyons, YA; Mangala, LS; Nagaraja, AS; Ravi, V; Siedel, JH; Sood, AK; Wagner, MJ; Wang, WL | 1 |
| Asokan, N; Bahram, S; Busnelli, I; Carapito, R; Follain, G; Garcia-Leon, MJ; Gensbittel, V; Goetz, JG; Larnicol, A; Lefebvre, O; Mercier, L; Osmani, N; Paul, N; Pichot, A | 1 |
| Adjei, A; Costello, BA; Doyle, LA; Erlichman, C; Fiskum, J; Haluska, P; Hubbard, JM; Ivy, P; Lin, G; Menefee, M; Qin, R; Reid, JM; Schenk, EL; Strand, C; Yin, J | 1 |
| Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Irani, S; Kashani, B; Momeny, M; Mousavi, SA; Shamsaiegahkani, S; Yousefi, H | 1 |
| Anastasia, A; Arnold, S; Bani, MR; Barry, ST; Bizzaro, F; Cavallaro, U; Damia, G; Fuso Nerini, I; Galbiati, A; Ghilardi, C; Giavazzi, R; Guana, F; Guffanti, F; Hattersley, MM; Leo, E; Minoli, L; Ostano, P; Ramos-Montoya, A; Russo, M; Taylor, MA; Urosevic, J; Williamson, SC | 1 |
| Chhabra, A; Eisen, T; Fife, K; Gallagher, FA; Matakidou, A; Mitchell, TJ; Mossop, H; Oades, G; Ortuzar, MC; Protheroe, A; Sala, E; Sipple, JAN; Skells, R; Stewart, GD; Stone, J; Sullivan, M; Thomas, MG; Ursprung, S; Venugopal, B; Walker, A; Warren, AY; Wason, J; Welsh, SJ; Young, G | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Asgrimsdottir, GM; Kristinsdottir, IM; Loftsson, T; Lorenzo-Soler, L; Olafsdottir, OB; Praphanwittaya, P; Stefansson, E | 1 |
| Atkinson, T; Berlin, S; Campos, SM; Horowitz, N; Krasner, CN; Lee, H; Lou, W; Meegan, K; Penson, RT; Pereira, L; Tyburski, K; Whalen, C | 1 |
| Balkwill, FR; Berlato, C; Gopinathan, G; Laforets, F; Lakhani, A; Maniati, E; Pedrosa, AR; Pegrum, C; Szabova, L | 1 |
| Brown, J; Chapman, J; Diaz, JP; Dymond, M; Ghamande, S; Kendrick, J; Kumar, S; Lee, JM; Liu, JF; Lowe, ES; Milenkova, T; Moore, RG; Park, MS; Slomovitz, BM; Tewari, KS | 1 |
| Augustine, B; Chawla, SP; Chen, AP; Do, K; Doroshow, JH; George, S; Ivy, SP; Juwara, L; Keohan, ML; Kuhlmann, L; Kummar, S; Movva, S; Nguyen, J; O'Sullivan Coyne, G; Patel, SR; Razak, A; Steinberg, SM; Takebe, N | 1 |
| Maleddu, A; Wilky, BA | 1 |
38 review(s) available for quinazolines and cediranib
| Article | Year |
|---|---|
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Anti-angiogenic and anti-HER therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Risk Assessment; Survival Analysis; Thoracic Neoplasms | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Topics: Brain Edema; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
Stratifying osteosarcoma: minimizing and maximizing therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dacarbazine; Humans; Integrins; Osteosarcoma; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survivors; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Targeted therapy in brain metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Humans; Ipilimumab; Lapatinib; Molecular Targeted Therapy; Neovascularization, Pathologic; Quinazolines | 2012 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Topics: Alanine; Antineoplastic Agents; Benzimidazoles; Carcinoma, Squamous Cell; Gene Amplification; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Quinolones; Receptors, Fibroblast Growth Factor; Signal Transduction; Triazines | 2013 |
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Disease Progression; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Biological; Myeloid Cells; Neoplasm Proteins; Neovascularization, Pathologic; Patient Selection; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Tumor Microenvironment; Vascular Endothelial Growth Factors | 2013 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Progress of molecular targeted therapies for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Cediranib in ovarian cancer: state of the art and future perspectives.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2016 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.
Topics: Animals; Antineoplastic Agents; Humans; Protein Kinase Inhibitors; Quinazolines | 2017 |
The role of Cediranib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Evaluation, Preclinical; Female; Humans; Ovarian Neoplasms; Quinazolines | 2017 |
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines | 2019 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
98 trial(s) available for quinazolines and cediranib
| Article | Year |
|---|---|
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.
Topics: Administration, Oral; Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gefitinib; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pelvic Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Tomography, Spiral Computed | 2007 |
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2007 |
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dendritic Cells; Female; Flow Cytometry; Gefitinib; Humans; Male; Middle Aged; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2009 |
Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2009 |
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Diarrhea; Fatigue; Female; Humans; Hypertension; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Topics: Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Prospective Studies; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A; Young Adult | 2009 |
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines | 2010 |
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Blood Pressure; Carcinoma; Chi-Square Distribution; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
Topics: Antineoplastic Agents; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Proportional Hazards Models; Quinazolines | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2010 |
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; United States | 2010 |
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2011 |
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Quinazolines; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Child; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2010 |
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Topics: Adult; Aged; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Fasting; Female; Food-Drug Interactions; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Quinazolines; Survival Rate | 2012 |
T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Contrast Media; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Angiography; Male; Quinazolines; Radiography; Survival Rate | 2011 |
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2011 |
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Colorectal Neoplasms; Demography; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2012 |
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate | 2011 |
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2012 |
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2012 |
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Treatment Outcome; Tumor Burden | 2012 |
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Mesothelioma; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Humans; Iohexol; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Needle; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Patient Selection; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; Young Adult | 2013 |
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Topics: Adult; Aged; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; International Agencies; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Quinazolines; Salvage Therapy; Survival Rate; Young Adult | 2013 |
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Demography; Disease Progression; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Cediranib for metastatic alveolar soft part sarcoma.
Topics: Adult; Anorexia; Antineoplastic Agents; Diarrhea; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Hypertension; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prospective Studies; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Alveolar Soft Part; Treatment Outcome; Young Adult | 2013 |
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2013 |
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Carcinoma, Ovarian Epithelial; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Tablets; Treatment Outcome | 2013 |
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; International Agencies; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2013 |
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Blood Vessels; Brain; Glioblastoma; Humans; Magnetic Resonance Angiography; Microcirculation; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2013 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaloacetates; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Magnetic Resonance Imaging; Oxygen; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Isoenzymes; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leucovorin; Organoplatinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Ascites; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Palliative Care; Paracentesis; Pleural Effusion; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cerebral Hemorrhage; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Quinazolines; Sarcoma; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2014 |
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate | 2015 |
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines | 2015 |
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult | 2015 |
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Canada; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom | 2015 |
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2015 |
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
Topics: Administration, Oral; Adolescent; Biological Availability; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic; Time Factors; Young Adult | 2015 |
Diffusion-weighted MR imaging of metastatic abdominal and pelvic tumours is sensitive to early changes induced by a VEGF inhibitor using alternative diffusion attenuation models.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Humans; Magnetic Resonance Imaging; Middle Aged; Models, Theoretical; Pelvic Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions.
Topics: Abdominal Neoplasms; Adult; Aged; Algorithms; Antineoplastic Agents; Aorta; Computer Simulation; Contrast Media; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms | 2015 |
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
Topics: Aged; Benzodioxoles; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Quinazolines; Vascular Endothelial Growth Factor A | 2016 |
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Quinazolines; Treatment Outcome | 2016 |
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A | 2016 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escala
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Quinazolines | 2017 |
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kidney Neoplasms; Male; Prognosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Hypertension; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum Compounds; Progression-Free Survival; Quinazolines; Response Evaluation Criteria in Solid Tumors; Time Factors | 2019 |
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2019 |
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Quinazolines; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Young Adult | 2019 |
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Rectal Neoplasms; Tissue Distribution | 2019 |
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Progression-Free Survival; Quinazolines | 2019 |
Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
Topics: Adolescent; Antineoplastic Agents; Child; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Prognosis; Quinazolines; Sarcoma, Alveolar Soft Part; Survival Rate | 2019 |
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherap
Topics: Adult; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2021 |
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Topics: Clinical Trials, Phase II as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2021 |
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factors | 2022 |
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biopsy; Capillary Permeability; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Magnetic Resonance Imaging; Medical Futility; Nephrectomy; Non-Randomized Controlled Trials as Topic; Phthalazines; Piperazines; Proof of Concept Study; Quinazolines; Treatment Outcome; Tumor Burden | 2021 |
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Humans; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2022 |
115 other study(ies) available for quinazolines and cediranib
| Article | Year |
|---|---|
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Topics: Administration, Oral; Animals; Biological Availability; Bone Development; Cell Proliferation; Corpus Luteum; Endothelial Cells; Extracellular Matrix Proteins; Female; Humans; Mice; Myosin Heavy Chains; Neoplasms; Nonmuscle Myosin Type IIB; Phosphorylation; Protein Kinase Inhibitors; Proteins; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2005 |
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer.
Topics: Breast Neoplasms; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Humans; Inflammation; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor | 2005 |
A physiologic imaging pilot study of breast cancer treated with AZD2171.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice; Neovascularization, Pathologic; Pilot Projects; Positron-Emission Tomography; Quinazolines; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.
Topics: Adenoma; Animals; Female; Genes, APC; Intestinal Neoplasms; Intestinal Polyps; Male; Mice; Mice, Inbred C57BL; Quinazolines; RNA, Messenger; Signal Transduction; Splenomegaly; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Radiation; Endothelial Cells; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred CBA; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Survival Rate; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2008 |
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Topics: Animals; Calibration; Cell Proliferation; Colonic Neoplasms; Contrast Media; Disease Models, Animal; Heart Ventricles; Hemodynamics; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Organometallic Compounds; Piperidines; Quinazolines; Rats; Rats, Nude | 2008 |
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimerization; Gefitinib; Humans; Mice; Mice, Inbred Strains; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Topics: Animals; Apoptosis; Carcinoma; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Quinazolines; Survival Rate; Thyroid Neoplasms; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Antibodies, Phospho-Specific; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Phosphotyrosine; Quinazolines; Reproducibility of Results; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Topics: Angiogenesis Inhibitors; Animals; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Captopril; Cell Line, Tumor; Colorectal Neoplasms; Humans; Hypertension; Mice; Nifedipine; Quinazolines; Rats; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Topics: Adenoviridae; Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Membrane Permeability; Cell Movement; Cell Proliferation; Cell Survival; Endothelium, Vascular; Humans; Immunoprecipitation; Lymphangiogenesis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Signal Transduction; Skin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Topics: Animals; Base Sequence; Cell Line, Tumor; DNA Primers; Lymphatic Metastasis; Mice; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Tongue Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Dose-Response Relationship, Drug; Gadolinium DTPA; Glioma; Humans; Magnetic Resonance Imaging; Quinazolines; Rats; Rats, Nude; Treatment Outcome | 2009 |
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
Topics: Animals; Apoptosis; Carcinoma; Combined Modality Therapy; Female; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2009 |
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Endothelium, Vascular; Humans; Kidney Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Fluorescent Dyes; Humans; Indicators and Reagents; Multidrug Resistance-Associated Proteins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; RNA Interference; Tetrazolium Salts; Thiazoles | 2009 |
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.
Topics: Animals; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Ferric Compounds; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Topics: Animals; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Glioblastoma; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2009 |
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Antineoplastic Agents; Biomarkers; Blood Volume; Brain Neoplasms; Collagen; Disease-Free Survival; Glioblastoma; Hematologic Tests; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Neoplasm Invasiveness; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2009 |
Acoustic radiation force and optical spectroscopy for assessing tumor vessel normalization during anti-angiogenic therapy.
Topics: Acoustics; Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Cell Line, Tumor; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis; Treatment Outcome | 2009 |
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Disease Models, Animal; Female; Immunoenzyme Techniques; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2009 |
Characterisation and identification of the human N+-glucuronide metabolite of cediranib.
Topics: Animals; Dogs; Female; Glucuronides; Guinea Pigs; Hepatocytes; Humans; Macaca fascicularis; Macaca mulatta; Magnetic Resonance Spectroscopy; Male; Mice; Quinazolines; Rabbits; Rats; Rats, Wistar; Swine; Swine, Miniature; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
Topics: Adult; Animals; Cells, Cultured; Cytochrome P-450 Enzyme System; Dogs; Female; Glucuronosyltransferase; Guinea Pigs; Hepatocytes; Humans; Liver; Macaca fascicularis; Macaca mulatta; Male; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Mice; Microsomes, Liver; Middle Aged; Oxygenases; Quinazolines; Rabbits; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Species Specificity; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A | 2010 |
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
Topics: Animals; Blotting, Western; Bone Neoplasms; Brain Neoplasms; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Proteins; Piperidines; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Cell Line, Tumor; Cell Proliferation; Diffusion; Disease Models, Animal; Extracellular Space; Glioma; Humans; Magnetic Resonance Imaging; Mice; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; fms-Like Tyrosine Kinase 3; HEK293 Cells; Humans; Ligands; Lung; Mice; Mice, Nude; NIH 3T3 Cells; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Stem Cell Factor; Xenograft Model Antitumor Assays | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Dacarbazine; ErbB Receptors; Glioma; Humans; Immunoblotting; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; X-Rays | 2011 |
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Topics: Adolescent; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Glioblastoma; Humans; Infant; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Glioblastoma; Humans; Quinazolines; Treatment Outcome | 2011 |
Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Liquid-Liquid Extraction; Mice; Quinazolines; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Growth Inhibitors; Humans; Lymphokines; Male; Mice; Mice, SCID; Platelet-Derived Growth Factor; Prostatic Neoplasms; Quinazolines; Random Allocation; Xenograft Model Antitumor Assays | 2012 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biomarkers, Tumor; Contrast Media; Dextrans; Fluorescent Dyes; Glioma; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Nitroimidazoles; Quinazolines; Radiation-Sensitizing Agents; Rats; Rats, Nude; Tumor Cells, Cultured | 2012 |
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Cell Membrane Permeability; Dogs; Humans; Mice; Mice, Knockout; Quinazolines; Tissue Distribution | 2012 |
Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Janus Kinase 1; Janus Kinase 2; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasms, Experimental; Pyrazoles; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Topics: Animals; Benzamides; Chromatography, Liquid; Glucuronides; Humans; Linear Models; Mice; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Female; Glioblastoma; Humans; Immunohistochemistry; Intermediate Filament Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Nude; Nerve Tissue Proteins; Nestin; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Mice; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Codon; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Treatment Outcome | 2013 |
The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients.
Topics: Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Quinazolines; Sarcoma, Alveolar Soft Part | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Dacarbazine; Drug Synergism; Extracellular Fluid; Glioma; Humans; Male; Microdialysis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Mice; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Sequence Analysis, RNA; Species Specificity; Xenograft Model Antitumor Assays | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bayes Theorem; Brain; Drug Delivery Systems; Mice; Models, Biological; Quinazolines | 2014 |
Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Capillary Permeability; Drug Synergism; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Quinacrine; Quinazolines; Tumor Burden; Tumor Cells, Cultured | 2013 |
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Hypertension; Male; Niacinamide; Phenylurea Compounds; Quinazolines; Rats; Rats, Wistar; Risk; Signal Transduction; Sorafenib; Telemetry; Vascular Endothelial Growth Factor A | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Male; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms | 2014 |
VEGF-dependent and PDGF-dependent dynamic neurovascular reconstruction in the neurohypophysis of adult mice.
Topics: Animals; Arginine Vasopressin; Cell Proliferation; Endothelium, Vascular; Male; Mice; Mice, Inbred C57BL; Models, Animal; Neovascularization, Physiologic; Neuroglia; Oxytocin; Pituitary Gland, Posterior; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2014 |
Drug combo may be effective in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines | 2014 |
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Colorectal Neoplasms; Humans; Quinazolines; Treatment Outcome | 2014 |
Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Enzyme Activation; Glioma; Mice; Proto-Oncogene Proteins c-akt; Quinacrine; Quinazolines; Vacuoles | 2014 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Cediranib aims for a comeback.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss | 2015 |
Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Endometriosis; Female; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Glioblastoma; Glycolates; Humans; Lactic Acid; Male; Mice; Mice, Nude; Microspheres; Polyesters; Polymers; Protein Kinase Inhibitors; Quinazolines; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2015 |
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Brain Neoplasms; Cells, Cultured; Dexamethasone; Drug Delivery Systems; Drug Liberation; Edema; Female; Glioma; Human Umbilical Vein Endothelial Cells; Protein Kinase Inhibitors; Quinazolines; Rats, Inbred F344 | 2015 |
Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; High-Throughput Screening Assays; Humans; Indoles; Melanoma; Mice; Molecular Targeted Therapy; Proto-Oncogene Proteins B-raf; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Cell Line, Tumor; Colorectal Neoplasms; Humans; Kaplan-Meier Estimate; Leptin; Melanoma, Experimental; Mice; Mice, Obese; Proportional Hazards Models; Quinazolines; Retrospective Studies; Transcriptome; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Glioma; Mice; Quinazolines; Semicarbazones | 2015 |
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glioblastoma; Macrophages; Mice; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic | 2016 |
MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Screening Assays, Antitumor; Female; Gene Ontology; Humans; Inhibitory Concentration 50; MicroRNAs; Quinazolines; Transcriptome | 2016 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; HT29 Cells; Humans; Male; Mice; Mice, Nude; Microvessels; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Body Weight; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Male; Middle Aged; Models, Biological; Neoplasms; Polypharmacy; Protein Kinase Inhibitors; Quinazolines; Rifampin; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
Normalizing Tumor Vessels To Increase the Enzyme-Induced Retention and Targeting of Gold Nanoparticle for Breast Cancer Imaging and Treatment.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Gold; Human Umbilical Vein Endothelial Cells; Humans; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Optical Imaging; Permeability; Photoacoustic Techniques; Quinazolines; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform.
Topics: Antineoplastic Agents; Astrocytes; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Glioblastoma; High-Throughput Screening Assays; Humans; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2017 |
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Female; Humans; Male; Markov Chains; Middle Aged; Neoplasms; Probability; Protein Kinase Inhibitors; Quinazolines; Time Factors; Young Adult | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.
Topics: Antibodies, Monoclonal; Autopsy; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Pulmonary Veno-Occlusive Disease; Quinazolines; Thrombotic Microangiopathies; Uterine Cervical Neoplasms | 2018 |
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Mice, SCID; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Quinazolines; Thiosemicarbazones; Xenograft Model Antitumor Assays | 2018 |
D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma.
Topics: Animals; Bilirubin; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Collagen Type IV; Drug Carriers; Glioma; Humans; Male; Mice; Nanoparticles; Paclitaxel; Peptide Fragments; Quinazolines | 2019 |
Technology Applications: Use of Digital Health Technology to Enable Drug Development.
Topics: Biomedical Technology; Diarrhea; Drug Development; Early Diagnosis; Female; Humans; Hypertension; Mobile Applications; Ovarian Neoplasms; Patient Portals; Patient Satisfaction; Pilot Projects; Quinazolines; Research Design; Surveys and Questionnaires; Telemedicine | 2018 |
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Humans; Medical Oncology; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2020 |
Chemotherapy-free treatments: are we ready for prime time?
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time | 2019 |
Secondary polycythemia in a sarcoma patient: a commentary about cediranib.
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Male; Middle Aged; Polycythemia; Protein Kinase Inhibitors; Quinazolines; Sarcoma, Alveolar Soft Part | 2019 |
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.
Topics: Angiogenesis Inhibitors; Animals; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neoplasms, Experimental; Neuroblastoma; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2019 |
VEGF- and PDGF-dependent proliferation of oligodendrocyte progenitor cells in the medulla oblongata after LPC-induced focal demyelination.
Topics: Animals; Cell Division; Demyelinating Diseases; Imatinib Mesylate; Lateral Ventricles; Lipopolysaccharides; Male; Medulla Oblongata; Mice; Mice, Inbred C57BL; Myelin Sheath; Neural Stem Cells; Oligodendrocyte Precursor Cells; Platelet-Derived Growth Factor; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remyelination; Specific Pathogen-Free Organisms; Vascular Endothelial Growth Factor A | 2019 |
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; DNA Repair; Down-Regulation; E2F4 Transcription Factor; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Rad51 Recombinase; Receptors, Platelet-Derived Growth Factor; Tumor Hypoxia; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2019 |
Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice.
Topics: Double-Blind Method; Humans; Quinazolines; Sarcoma, Alveolar Soft Part | 2019 |
Comparison of the ligand-binding properties of fluorescent VEGF-A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET.
Topics: Binding Sites; Bioluminescence Resonance Energy Transfer Techniques; Cell Membrane; Cells, Cultured; Dose-Response Relationship, Drug; Endosomes; Fluorescence; HEK293 Cells; Humans; Ligands; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Mechanism of Cediranib-Olaparib Combo Revealed.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Down-Regulation; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Rad51 Recombinase | 2019 |
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Data Accuracy; Data Collection; Double-Blind Method; Drug Approval; Female; Humans; Marketing; Ovarian Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quinazolines; Registries; Retrospective Studies; Survival Rate | 2019 |
Cediranib Maleate-From Crystal Structure Toward Materials Control.
Topics: Crystallization; Maleates; Particle Size; Pharmaceutical Preparations; Quinazolines | 2020 |
The Noonan Syndrome Gene
Topics: Animals; Blood Vessels; Carcinoma, Lewis Lung; Disease Models, Animal; Endosomal Sorting Complexes Required for Transport; Endosomes; Endothelial Cells; Haploinsufficiency; HeLa Cells; Hemorrhage; Humans; Lymphokines; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Noonan Syndrome; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; Transcription Factors; Ubiquitination; Vascular Endothelial Growth Factor Receptor-2; Vascular Malformations | 2020 |
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Docetaxel; Gamma Rays; Gene Expression Regulation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor | 2020 |
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Topics: Adenocarcinoma; Female; Humans; Mutation; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro.
Topics: A549 Cells; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Signaling System; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2021 |
Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Prognosis; Pyridones; Pyrimidinones; Quinazolines; Transcriptome; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2021 |
Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells.
Topics: Animals; Animals, Genetically Modified; Blood Flow Velocity; Embryo, Nonmammalian; Endothelium, Vascular; Gene Expression Regulation, Neoplastic; Gene Ontology; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Intravital Microscopy; Microfluidics; Microscopy, Confocal; Neoplastic Cells, Circulating; Quinazolines; RNA, Neoplasm; Signal Transduction; Sunitinib; Transendothelial and Transepithelial Migration; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2021 |
Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioblastoma; Growth Inhibitors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2021 |
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2021 |
Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye.
Topics: Administration, Topical; Animals; Cyclodextrins; gamma-Cyclodextrins; Indoles; Maleates; Nanoparticles; Ophthalmic Solutions; Protein Kinase Inhibitors; Quinazolines; Rabbits; Retina; Vascular Endothelial Growth Factor A | 2022 |
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Interleukin-6; Mice; Ovarian Neoplasms; Programmed Cell Death 1 Receptor; Quinazolines; Tumor Microenvironment | 2022 |
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Topics: Adolescent; Adult; Bevacizumab; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Indoles; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines | 2022 |
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
Topics: Humans; Indoles; Protein Kinase Inhibitors; Quinazolines; Sarcoma, Alveolar Soft Part; Sunitinib | 2023 |
Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022.
Topics: Antineoplastic Agents; Humans; Quinazolines; Sarcoma, Alveolar Soft Part; Sunitinib | 2023 |